cyclobenzaprine hydrochloride

ApprovedSmall molecule

NNeurana Pharmaceuticals, Inc.

cyclobenzaprine hydrochloride is one of 41 small molecule programs targeting Muscle spasm. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Muscle SpasmActive, not recruiting

MigraineActive, not recruiting

Muscle SpasmApproved

Active, not recruiting

MigrainePhase 3

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

cyclobenzaprine hydrochloride

NNeurana Pharmaceuticals, Inc.

Approved

1 2

Aimovig

Amgen

Preclinical

33 3

Emgality

Eli Lilly

Preclinical

19 4

Vyepti

Lundbeck

Preclinical

12 5

Bayer Aspirin

Bayer

Preclinical

2 6

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 7

Botox

RRevance Therapeutics, Inc.

Preclinical

9 8

Viagra

VViatris Specialty LLC

Preclinical

2 9

Pristiq

PPrism Pharmaceuticals

Preclinical

1 10

Botulinum Toxin a

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Temporomandibular Disorders1 trial

Analysis of the Effects of the Osteopathic Manipulative Treatment in Carriers of Temporomandibular Disorders

Completed·IInstituto Brasileiro de Osteopatia·N/A·NCT02974166·32 enrolled

Cognitive Function1 trial

Effects of Tolperisone on Measures of Drowsiness and Cognitive Function

Completed·NNeurana Pharmaceuticals, Inc.·Phase 1·NCT04407377·39 enrolled

Fasting Conditions1 trial

Bioequivalence Study of Cyclobenzaprine Hydrochloride 10 mg Tablets, USP Under Fasting Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT00778037·40 enrolled

Muscle spasm1 trial

An Effectiveness and Safety Study of Cyclobenzaprine HCl Alone or in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm

Completed·MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.·Phase 4·NCT00246389·1,000 enrolled

Migraine1 trial

Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine

Terminated·KKennedy Medical Group·Phase 3·NCT01151787·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for cyclobenzaprine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cyclobenzaprine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cyclobenzaprine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neurana Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNeurana Pharmaceuticals, Inc.

cyclobenzaprine hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Temporomandibular Disorders1 trial

Cognitive Function1 trial

Fasting Conditions1 trial

Muscle spasm1 trial

Migraine1 trial

References

Drug Info

Quick Facts

Related News